Sign In
Buy EXEL
$51.60
+3.06 (+6.30%)
At Close: Jun 03, 2026
Here's Why Exelixis (EXEL) is a Strong Growth Stock
10:45am, Wednesday, 23'rd Jul 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
What Analyst Projections for Key Metrics Reveal About Exelixis (EXEL) Q2 Earnings
10:16am, Wednesday, 23'rd Jul 2025
Get a deeper insight into the potential performance of Exelixis (EXEL) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some
EXEL vs. ARGX: Which Stock Should Value Investors Buy Now?
12:41pm, Monday, 21'st Jul 2025
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and argenex SE (ARGX). But which of these two stocks offers value investors a better bang for
Exelixis (EXEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
11:00am, Monday, 21'st Jul 2025
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why This $50 Healthcare Stock Could Be the Next $200 Winner
06:30am, Sunday, 20'th Jul 2025
A decade ago, shares of Exelixis (EXEL -0.89%), a biotech company specializing in oncology, were trading for under $10 per share. Today, the drugmaker's shares are changing hands for about $45 apiece.
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?
01:10pm, Tuesday, 15'th Jul 2025
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025
04:05pm, Monday, 14'th Jul 2025
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2025 financial results will be released on Monday, July 28, 2025 after the markets close. At 5:0
Exelixis (EXEL) is an Incredible Growth Stock: 3 Reasons Why
01:46pm, Monday, 14'th Jul 2025
Exelixis (EXEL) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
10:50am, Thursday, 10'th Jul 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks
09:16am, Tuesday, 08'th Jul 2025
Top-ranked stocks Urban Outfitters (URBN), Fox (FOX), Electronic Arts (EA), Uber Technologies (UBER) and Exelixis (EXEL) are likely to beat on the bottom line in their upcoming releases.
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term
10:46am, Monday, 07'th Jul 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Exelixis Surges 35.2% in Three Months: Buy or Sell the Stock?
10:26am, Monday, 07'th Jul 2025
EXEL surges 35.2% in three months as strong Cabometyx sales and zanzalintinib trial success fuel investor optimism.
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?
10:40am, Friday, 04'th Jul 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
2 Stocks to Buy With Less Than $50
07:45am, Friday, 04'th Jul 2025
One formula to generate strong returns on equity markets involves investing small amounts of money in top stocks regularly over long periods. Buying fractional shares is one way to apply this strategy
EXEL or ARGX: Which Is the Better Value Stock Right Now?
12:41pm, Thursday, 03'rd Jul 2025
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and argenex SE (ARGX). But which of these two companies is the best option for those
